Groundbreaking Dual-Cell Immunotherapy Shows Promise in Advanced Solid Tumor Treatment

Breaking New Ground in Dual-Cell Immunotherapy: A Promising Approach for Solid Tumors?

UCLA researchers have demonstrated the first successful use of dual-cell immunotherapy combining traditional transgenic T cells with hematopoietic stem cells (HSCs) in patients with advanced solid tumors. The Phase I trial showed that the approach was safe and feasible, with HSC-derived T cells demonstrating functional anti-tumor activity against NY-ESO-1-positive tumors. Despite early evidence of clinical response in two of three treated patients, the therapy faced significant logistical challenges and safety concerns related to the conditioning regimen required for HSC engraftment.

The novel therapeutic approach addressed a fundamental limitation in current T cell therapies for solid tumors – their lack of persistence and durable anti-tumor activity. Traditional TCR-T cell therapies often show initial objective responses but frequently lose effectiveness within 6-12 months as transgenic T cells decline or become functionally exhausted. By combining immediate anti-tumor activity from conventional TCR-T cells with a continuous supply of fresh TCR-expressing T cells derived from engineered HSCs, the UCLA team aimed to create a more sustainable therapeutic effect. The study utilized a lentiviral vector to introduce both the NY-ESO-1 TCR and a modified herpes simplex virus thymidine kinase (sr39TK) into autologous HSCs, allowing for non-invasive tracking of cell engraftment through PET imaging while providing a safety mechanism to eliminate the cells if necessary. This represented the first clinical demonstration of this imaging capability in humans receiving gene-modified HSCs, offering valuable insights into real-time monitoring of cellular therapies.

The trial enrolled five patients with NY-ESO-1-positive advanced solid tumors, primarily sarcomas, with three ultimately receiving the dual-cell therapy. Patients underwent mobilized leukapheresis to collect peripheral blood stem cells (PBSCs), which were then transduced with the lentiviral vector encoding the NY-ESO-1 TCR and sr39TK gene. Following lot release testing, patients underwent unmobilized leukapheresis to collect peripheral blood mononuclear cells (PBMCs), which were separately transduced with a retroviral vector encoding the same NY-ESO-1 TCR. Patients received myeloablative conditioning with busulfan and fludarabine before receiving the engineered HSCs on day 0 and the TCR-T cells on day +1, followed by low-dose IL-2 administration. Two patients who consented did not ultimately receive treatment – one failed to mobilize sufficient CD34+ cells despite repeated attempts, while another developed a malignant pleural effusion requiring drainage and withdrew from the study. This highlighted the challenges of applying such intensive therapies in heavily pre-treated patients with advanced disease.

What Are the Key Clinical and Molecular Findings in the Trial?

Safety data from the trial showed no grade 3 or greater adverse events attributed to the transgenic HSCs, though one grade 3 adverse event (hypotension) was possibly related to the TCR-T cell infusion. Multiple grade 4 adverse events occurred due to the conditioning chemotherapy and resulting immunosuppression, consistent with the known toxicity profile of busulfan and fludarabine. One patient (NYSCT-03) developed grade 4 hypoxia on day +62 due to cytomegalovirus pneumonitis that was refractory to antiviral treatment, resulting in death on day +76. This serious complication highlighted the significant immunosuppression associated with the conditioning regimen and the vulnerability of patients to opportunistic infections during immune reconstitution. The other patients experienced disease progression within 2-2.5 months, though two patients showed evidence of transient tumor reduction on PET/CT imaging before progression.

The investigators successfully demonstrated the biological activity of their approach through sophisticated analyses. Using digital droplet PCR to distinguish between retroviral and lentiviral vector signatures, they showed that initial T cell expansion was dominated by the retroviral TCR-T cell product, but later shifted toward lentiviral-derived cells in patients with successful HSC engraftment. PET imaging with [18F]-FHBG confirmed engraftment of sr39TK-expressing HSCs in the bone marrow of two patients. Single-cell RNA and ATAC sequencing of one patient's blood cells at day +43 revealed that nearly 47% of nucleated cells contained lentiviral signatures, confirming they originated from the engineered HSCs. These HSC-derived T cells demonstrated specific anti-tumor functionality when stimulated with NY-ESO-1-positive, HLA-A*02:01-positive tumor cells in laboratory tests, validating the core hypothesis that functional TCR-expressing T cells could develop from engineered stem cells.

What Insights Do Leading Experts Provide?

Dr. Antoni Ribas, senior author of the study, noted: "This represents a significant advance in our ability to generate long-lived, functional T cells targeting cancer antigens. While the approach faces logistical challenges, the proof-of-concept that engineered HSCs can give rise to functional anti-tumor T cells opens new avenues for sustained cellular immunotherapy." The researchers also highlighted the first successful clinical use of the sr39TK reporter gene to track engraftment of genetically modified HSCs in humans, providing a valuable tool for monitoring cellular therapies non-invasively.

How Does This Innovation Compare to Existing Therapies?

The approach stands in contrast to conventional CAR-T and TCR-T therapies that rely solely on differentiated T cells. Companies like Adaptimmune, whose afamitresgene autoleucel (a traditional NY-ESO-1 TCR-T therapy) recently received FDA approval for synovial sarcoma, have demonstrated the clinical utility of targeting NY-ESO-1 but face similar challenges with long-term efficacy. The UCLA approach potentially offers advantages in terms of sustained T cell production but comes with significant added complexity and toxicity from the HSC conditioning regimen. Other companies exploring HSC-based approaches for genetic disorders, such as bluebird bio and CRISPR Therapeutics, have demonstrated the feasibility of lentiviral HSC modification but typically target conditions where the risk-benefit ratio more clearly favors intensive conditioning.

What Future Directions Could Elevate Cellular Immunotherapy?

Looking forward, the researchers suggested that the approach might be better suited for other indications where patients are less heavily pre-treated and medically fragile than those with advanced sarcomas. Potential applications include HIV-1 infection, where preclinical studies have shown promise for HSC-derived antigen-specific T cells targeting the virus. The team also noted that future iterations might explore CAR constructs instead of TCRs to avoid the partial allelic exclusion observed with TCR-transduced HSCs, though this would require careful evaluation of the effects of CAR expression in all HSC-derived lineages. The continued incorporation of safety features like suicide genes will remain essential for these advanced cellular engineering approaches.

Industry Context: This trial highlights both the promise and challenges of advanced cellular engineering approaches in oncology. While the biological proof-of-concept was achieved, the logistical complexity, manufacturing challenges, and safety concerns associated with myeloablative conditioning raise questions about commercial viability for solid tumors. The field continues to search for the optimal balance between therapeutic potency and safety, with increasing interest in "off-the-shelf" allogeneic approaches that might avoid some of the manufacturing and timing challenges seen in this autologous dual-product strategy. The successful use of the sr39TK reporter gene for in vivo imaging represents a valuable advance for monitoring cellular therapies that could be adopted more broadly across the industry.

Summary

The UCLA research team has achieved a significant breakthrough in cellular immunotherapy by successfully combining traditional transgenic T cells with hematopoietic stem cells (HSCs) in patients with advanced solid tumors. The Phase I trial demonstrated safety and feasibility, with HSC-derived T cells showing functional anti-tumor activity against NY-ESO-1-positive tumors. The study utilized innovative techniques, including a lentiviral vector system and PET imaging capabilities for monitoring cell engraftment. While two of three treated patients showed initial clinical response, the therapy faced challenges including logistical complexities and safety concerns related to the conditioning regimen. The research represents a potential solution to the persistence limitations of current T cell therapies, though questions remain about its commercial viability due to manufacturing challenges and safety considerations.